ImmunityBio Dividendes et rachats
Dividende contrôle des critères 0/6
ImmunityBio n'a pas d'antécédents de versement de dividendes.
Informations clés
n/a
Rendement du dividende
-6.8%
Rendement des rachats
| Rendement total pour l'actionnaire | -6.8% |
| Rendement futur des dividendes | n/a |
| Croissance des dividendes | n/a |
| Prochaine date de paiement du dividende | n/a |
| Date ex-dividende | n/a |
| Dividende par action | n/a |
| Ratio de distribution | n/a |
Mises à jour récentes sur les dividendes et les rachats
Recent updates
ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout
Summary ImmunityBio is transitioning into a scalable bladder cancer immunotherapy platform, driven by accelerating Anktiva adoption and robust revenue growth. 1Q26 revenue surged 168% YoY to $44.2M, with strong physician uptake, but operating expenses and adjusted net loss ($86.2M) remain elevated amid heavy investment. The papillary sBLA for Anktiva is a key near-term catalyst; regulatory uncertainty persists, but compelling QUILT-3.032 data and prior FDA approval in CIS support optimism. The Tokyo-172 BCG deal positions IBRX to resolve U.S. supply bottlenecks, enabling dual-source BCG infrastructure and global expansion, enhancing platform value. Read the full article on Seeking AlphaHere's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...
Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?
Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?
Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
NasdaqGS:IBRX 1 Year Share Price vs Fair Value Explore ImmunityBio's Fair Values from the Community and select yours A...ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
Summary ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities. Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval, and expanding bladder cancer market. Read the full article on Seeking AlphaImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential
Summary Anktiva received FDA approval in April 2024 for BCG-unresponsive NMIBC. Q3 revenue was $5.954 million, but high R&D and SG&A expenses led to an $80.253 million operational loss, with notable share dilution. Financial health shows a current ratio over 2.0, but high long-term debt and a $34 million monthly cash burn raise concerns. ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. IBRX remains a "sell" due to ongoing dilution, financial risks, and limited upside despite Anktiva's potential in NMIBC. Read the full article on Seeking AlphaImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful
Summary ImmunityBio's Anktiva shows promise in cancer immunotherapy, with initial sales of $900K and ongoing studies in various cancers, including non-small cell lung cancer. Despite high debt and cash burn, friendly debt terms from entities connected to the founder mitigate financial risks, maintaining shareholder value. The company's novel platforms, like the CD19 t-haNK therapy, diversify its pipeline, reducing reliance on Anktiva alone for future growth. While IBRX has significant upside potential, any negative news could deflate the stock's hype-driven valuation, making it a high-risk investment. Read the full article on Seeking AlphaImmunityBio: Moving The Needle
Summary ImmunityBio's ANKTIVA shows promising commercial and clinical progress, with expanded patient access and potential EU/UK regulatory filings, enhancing its global market penetration and revenue prospects. Recent positive clinical data for ANKTIVA in NSCLC and endometrial cancer trials highlight its potential beyond bladder cancer, boosting its long-term growth outlook. Despite significant advancements, risks include regulatory hurdles, commercialization challenges, high cash burn, and reliance on founder Dr. Patrick Soon-Shiong for funding. I plan to capitalize on the current sell-off, placing buy orders around $3.50-$4.00, and setting sell targets at $9 and $12.25 per share. Read the full article on Seeking AlphaImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
Summary Anktiva, ImmunityBio's lead molecule, shows promising results with a 71% CR rate and 100% survival at 24 months for BCG-unresponsive NMIBC. Despite Anktiva's potential, ImmunityBio faces financial challenges, relying heavily on loans from founder Dr. Soon-Shiong, leading to high indebtedness. The company has a market cap of $2.43bn but limited cash runway, raising concerns about its financial stability and lack of recent earnings calls. Anktiva's competitive position in a diversified NMIBC market is strong, but the financial entanglement with Dr. Soon-Shiong poses significant risks for retail investors. Read the full article on Seeking AlphaStabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de IBRX ont été stables dans le passé.
Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de IBRX ont augmenté.
Rendement des dividendes par rapport au marché
| ImmunityBio Rendement des dividendes par rapport au marché |
|---|
| Segment | Rendement du dividende |
|---|---|
| Entreprise (IBRX) | n/a |
| 25% du marché (US) | 1.4% |
| 25% du marché (US) | 4.3% |
| Moyenne du secteur (Biotechs) | 2.5% |
| Analyste prévisionnel (IBRX) (jusqu'à 3 ans) | n/a |
Dividende notable: Impossible d'évaluer le rendement des dividendes de IBRX par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.
Dividende élevé: Impossible d'évaluer le rendement des dividendes de IBRX par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.
Bénéfice distribué aux actionnaires
Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de IBRX afin de déterminer si les dividendes versés sont couverts par les bénéfices.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car IBRX n'a signalé aucun versement.
Découvrir des entreprises qui versent des dividendes élevés
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 01:43 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
ImmunityBio, Inc. est couverte par 8 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |